09:44 AM EST - Valeant Pharmaceuticals International, Inc. : announced that RedHill Biopharma Ltd. an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today provided an update on its RHB-106 tasteless solid oral formulation bowel preparation development program under the worldwide exclusive license agreement with Salix Pharmaceuticals Ltd., recently acquired by Valeant. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading unchanged at $326.70.
